drug
tapentadol hydrochloride ER
Marketedupdated 5mo agoby $COLL COLLEGIUM PHARMACEUTICAL, INC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 6Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for 4 indications.
all catalysts(58)
approval · 58
Nov 20, 2008
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Nov 9, 2009
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Nov 1, 2010
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Nov 1, 2010
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Aug 25, 2011
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jul 9, 2012
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Aug 28, 2012
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Oct 15, 2012
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Apr 15, 2013
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jul 11, 2013
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jul 11, 2013
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jul 11, 2013
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jul 11, 2013
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jul 11, 2013
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Oct 31, 2013
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Oct 31, 2013
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jan 16, 2014
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jan 16, 2014
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jan 16, 2014
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Apr 16, 2014
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Aug 19, 2014
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Nov 17, 2014
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Nov 17, 2014
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jun 26, 2015
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Apr 20, 2016
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Sep 30, 2016
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Dec 16, 2016
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Dec 16, 2016
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Dec 16, 2016
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
May 26, 2017
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Sep 18, 2018
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Sep 18, 2018
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Sep 18, 2018
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Sep 18, 2018
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Sep 18, 2018
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Sep 18, 2018
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Oct 7, 2019
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Oct 7, 2019
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Oct 7, 2019
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Mar 4, 2021
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Mar 4, 2021
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Mar 4, 2021
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jul 3, 2023
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jul 3, 2023
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Dec 15, 2023
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Dec 15, 2023
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Dec 15, 2023
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jun 14, 2024
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jun 14, 2024
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jun 14, 2024
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Oct 31, 2024
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Oct 31, 2024
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Oct 31, 2024
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Dec 22, 2025
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Dec 22, 2025
approval
$COLL22.02+0.82%
NUCYNTA (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Dec 22, 2025
approval
$COLL22.02+0.82%
NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — FDA approval
tapentadol hydrochloride ER
→
Jan 26, 2026
approval
TAPENTADOL HYDROCHLORIDE — FDA approval
tapentadol hydrochloride ER
→
Feb 10, 2026
approval
TAPENTADOL HYDROCHLORIDE — FDA approval
tapentadol hydrochloride ER
→
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 3, 2027
91 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (20)
- Mar 22, 2029patentUS 8536130*PED2.5y
- Mar 22, 2029patentUS 8536130*PED2.5y
- Mar 22, 2029patentUS 8536130*PED2.5y
- Mar 22, 2029patentUS 8536130*PED2.5y
- Mar 22, 2029patentUS 8536130*PED2.5y
- Oct 21, 2028patentUS 11344512*PED2.0y
- Oct 21, 2028patentUS 11344512*PED2.0y
- Oct 21, 2028patentUS 11344512*PED2.0y
- Oct 21, 2028patentUS 11344512*PED2.0y
- Oct 21, 2028patentUS 11344512*PED2.0y
- Sep 22, 2028method-of-use (U-1276)US 85361302.0y
- Sep 22, 2028method-of-use (U-1276)US 85361302.0y
- Sep 22, 2028method-of-use (U-1276)US 85361302.0y
- Sep 22, 2028method-of-use (U-1276)US 85361302.0y
- Sep 22, 2028method-of-use (U-1276)US 85361302.0y
- Apr 21, 2028method-of-use (U-3391)US 113445121.5y
- Apr 21, 2028method-of-use (U-3392)US 113445121.5y
- Apr 21, 2028method-of-use (U-3391)US 113445121.5y
- Apr 21, 2028method-of-use (U-3391)US 113445121.5y
- Apr 21, 2028method-of-use (U-3391)US 113445121.5y
FDA exclusivities (8)
- Jan 3, 2027PEDPediatric (6mo bonus)91d
- Jan 3, 2027PEDPediatric (6mo bonus)91d
- Jan 3, 2027PEDPediatric (6mo bonus)91d
- Jan 3, 2027PEDPediatric (6mo bonus)91d
- Jul 3, 2026NPPNew Product (3y)
- Jul 3, 2026NPPNew Product (3y)
- Jul 3, 2026NPPNew Product (3y)
- Jul 3, 2026NPPNew Product (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that